Alamar Biosciences Q3 2026 Results: Net Loss of $13.3M, Loss Widens
Alamar Biosciences reported total revenue of $89.0 million for the nine months ended September 30, 2026, representing significant growth compared to $49.2 million in the prior year period. Despite this growth, the company incurred a net loss of $47.9 million for the period as it continues to invest heavily in research, development, and commercial expansion.
- Key figure
- Net loss $13.3M